ELSEVIER

Toxicology Letters 102–103 (1998) 681–685

Toxicology Letters

Author index

Volumes 102–103 (1998)

Albertini, S., see Gocke, E. **102–103,** 375
Albuquerque, E.X., E.F.R. Pereira, M.F.M. Braga, H. Matsubayashi, M. Alkondon, Neuronal nicotinic receptors modulate synaptic function in the hippocampus and are sensitive to blockade by the convulsant strychnine and by the anti-Parkinson drug amantadine **102–103,** 211
Alkondon, M., see Albuquerque, E.X. **102–103,** 211
Alvinerie, M., see Pineau, T. **102–103,** 459
Ames, B.N., Micronutrients prevent cancer and delay aging **102–103,** 5
Anson, R.M., see Bohr, V. **102–103,** 47
Antil, S., see Servent, D. **102–103,** 199
Aschner, M., Immune and inflammatory responses in the CNS: modulation by astrocytes **102–103,** 283

Bar-Tana, J., see Hertz, R. **102–103,** 85
Barkhuizen, A., see Spencer, P.S. **102–103,** 515
Barratt, M.D., Integrating computer prediction systems with in vitro methods towards a better understanding of toxicology **102–103,** 617
Baud, F.J., Pharmacokinetic-pharmacodynamic relationships. How are they useful in human toxicology? **102–103,** 643
Bell, D.A., see Portier, C.J. **102–103,** 185
Berg, C., K. Halldin, B. Brunström, I. Brandt, Methods for studying xenoestrogenic effects in birds **102–103,** 671
Betton, G., see Olson, H. **102–103,** 535
Blackburn, A. see Board, P. **102–103,** 149
Blocker, Y.S., see Fox, D.A. **102–103,** 359
Board, P., A. Blackburn, L.S. Jermiin, G. Chelvanayagam, Polymorphism of phase II enzymes: identification of new enzymes and polymorphic variants by database analysis **102–103,** 149
Boekelheide, K., J. Lee, E.B. Shipp, J.H. Richburg, G. Li, Expression of Fas system-related genes in the testis during development and after toxicant exposure **102–103,** 503
Bohr, V., R.M. Anson, S. Mazur, G. Dianov, Oxidative DNA damage processing and changes with aging **102–103,** 47
Bourdette, D., see Spencer, P.S. **102–103,** 515
Braga, M.F.M., see Albuquerque, E.X. **102–103,** 211
Brandt, I., see Berg, C. **102–103,** 671
Brindle, R., see James, N.H. **102–103,** 91
Brockmöller, J., I. Cascorbi, R. Kerb, C. Sachse, I. Roots, Polymorphisms in xenobiotic conjugation and disease predisposition **102–103,** 173
Brunström, B., see Berg, C. **102–103,** 671
Bucholski, A., see Winneke, G. **102–103,** 423
Buckett, K.J., see Di Marco, P.N. **102–103,** 241
Bus, J.S., see Gollapudi, B.B. **102–103,** 479
Bushnell, P.J., see Tilson, H.A. **102–103,** 631

Capen, C.C., Correlation of mechanistic data and histopathology in the evaluation of selected toxic endpoints of the endocrine system **102–103,** 405
Carthew, P., R.E. Edwards, B.M. Nolan, New approaches to the quantitation of hypertrophy and hyperplasia in hepatomegaly **102–103,** 411
Cascorbi, I., see Brockmöller, J. **102–103,** 173
Chang, C-C., see Trosko, J.E. **102–103,** 71
Chelvanayagam, G., see Board, P. **102–103,** 149
Chételat, A.A., see Gocke, E. **102–103,** 375
Choisy-Rossi, C., P. Reisdorf, E. Yonish-Rouach, Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death **102–103,** 491
Chomarat, P., J.M. Rice, B.L. Slagle, C.P. Wild, Hepatitis B virus-induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein **102–103,** 595
Cohen, G.M., see Zhuang, J. **102–103,** 121
Collan, Y., Alternatives for morphometric and stereologic analysis in toxicopathology **102–103,** 393
Cone, E.J., Recent discoveries in pharmacokinetics of drugs of abuse **102–103,** 97
Connor, K., see Safe, S. **102–103,** 665
Corsini, E., C.L. Galli, Cytokines and irritant contact dermatitis **102–103,** 277
Costa, L.G., Biochemical and molecular neurotoxicology: relevance to biomarker development, neurotoxicity testing and risk assessment **102–103,** 417
Costet, P., see Pineau, T. **102–103,** 459
Critchlow, M.R., see Williams, G.T. **102–103,** 485

PII S0378-4274(98)000101-5

Cui, L., see Shirai, T. **102–103,** 441

Daly, A.K., K.S. Fairbrother, J. Smart, Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes **102–103,** 143
De Jong, W.H., see Van Loveren, H. **102–103,** 261
De Vries, I., see Meulenbelt, J. **102–103,** 35
de Silva, O., see LeClaire, J. **102–103,** 575
de Zeeuw, R.A., Recent developments in analytical toxicology: for better or for worse **102–103,** 103
Dean, J.H., J.R. Hincks, B. Remandet, Immunotoxicology assessment in the pharmaceutical industry **102–103,** 247
DeGeorge, J., Challenges in application of new approaches to carcinogenicity testing for pharmaceuticals **102–103,** 565
Denissenko, M.F., see Pfeifer, G.P. **102–103,** 447
Di Marco, P.N., B.G. Priestly, K.J. Buckett, Carcinogen risk assessment. Can we harmonise? **102–103,** 241
Dianov, G., see Bohr, V. **102–103,** 47
Dingley, K.H., see Turteltaub, K.W. **102–103,** 435
Duan, R., see Safe, S. **102–103,** 343
Duhme, H., S.K. Weiland, U. Keil, Epidemiological analyses of the relationship between environmental pollution and asthma **102–103,** 307

Edwards, R.E., see Carthew, P. **102–103,** 411
Eerikäinen, S., see Savolainen, K.M. **102–103,** 363
Ekman, L., The international harmonisation of guidelines in the future: a viewpoint from the industry **102–103,** 551
Endo, N., see Tanizawa, T. **102–103,** 399
Endou, H., Recent advances in molecular mechanisms of nephrotoxicity **102–103,** 29
Esdaile, D.J., Perspectives on the past, present and future of computer prediction in toxicology **102–103,** 609

Fairbrother, K.S., see Daly, A.K. **102–103,** 143
Ferrando-May, E., see Nicotera, P. **102–103,** 139
Fox, D.A., L. He, A.T. Poblenz, C.J. Medrano, Y.S. Blocker, D. Srivastava, Lead-induced alterations in retinal cGMP phosphodiesterase trigger calcium overload, mitochondria dysfunction and rod photoreceptor apoptosis **102–103,** 359
Fujimoto, R., see Tanizawa, T. **102–103,** 399

Gaido, K., see Safe, S. **102–103,** 665
Galli, C.L., see Corsini, E. **102–103,** 277
Galtier, P. see Pineau, T. **102–103,** 459
Garssen, J., see Van Loveren, H. **102–103,** 261
Gaylor, D.W., see Slikker Jr, W. **102–103,** 429
Gill, J.H., see James, N.H. **102–103,** 91
Gocke, E., S. Albertini, A.A. Chételat, S. Kirchner, W. Muster, The photomutagenicity of fluoroquinolones and other drugs **102–103,** 375
Gollapudi, B.B., W.T. Stott, B.L. Yano, J.S. Bus, Mode of action considerations in the use of transgenic animals for mutagenicity and carcinogenicity evaluations **102–103,** 479
Gonzalez, F.J., The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption **102–103,** 161
Gray Jr. L.E., Xenoendocrine disrupters: laboratory studies on male reproductive effects **102–103,** 331
Gray, Jr. L.E., Tiered screening and testing strategy for xenoestrogens and antiandrogens **102–103,** 677
Grewenow, R., see Spencer, P.S. **102–103,** 515

Hall, A.H., Computer modeling and computational toxicology in new chemical and pharmaceutical product development **102–103,** 623
Halldin, K., see Berg, C. **102–103,** 671
Hampton, M.B., S. Orrenius, Redox regulation of apoptotic cell death in the immune system **102–103,** 355
Han, S.H., see Lee, Y.W. **102–103,** 79
Harris, C.C., see Hussain, S.P. **102–103,** 219
Harrison, D.J., Life and death in the genesis of the tumour cell **102–103,** 115
Hartwig, A., Carcinogenicity of metal compounds: possible role of DNA repair inhibition **102–103,** 235
Hasmall, S.C., see James, N.H. **102–103,** 91
Hastings, K.L., What are the prospects for regulation in immunotoxicology? **102–103,** 267
He, L., see Fox, D.A. **102–103,** 359
Heck, D.E., see Laskin, D.L. **102–103,** 289
Hedge, V.L., see Williams, G.T. **102–103,** 485
Heinzow, B., see Winneke, G. **102–103,** 423
Hemminki, K., see Rajaniemi, H. **102–103,** 453
Hemminki, K., see Zhao, C. **102–103,** 591
Hertz, R., J. Bar-Tana, Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans **102–103,** 85
Hickman, J.A., see Pritchard, D.M. **102–103,** 19
Hincks, J.R., see Dean, J.H. **102–103,** 247
Holden, P.R., see James, N.H. **102–103,** 91
Holt, P.G., see McWilliam, A.S. **102–103,** 323
Hori, M., see Tanizawa, T. **102–103,** 399
Horii, I., Advantages of toxicokinetics in new drug development **102–103,** 657
Hussain, S.P., C.C. Harris, Molecular epidemiology of human cancer **102–103,** 219

Ingelman-Sundberg, M., Functional consequences of polymorphism of xenobiotic metabolising enzymes **102–103,** 155
Ito, N., see Shirai, T. **102–103,** 441

Jackman, A., see Pritchard, D.M. **102–103,** 19
Jaeger, A., Are kinetic investigations feasible in human poisoning **102–103,** 637
James, N.H., J.H. Gill, R. Brindle, N.J. Woodyatt, N. Macdonald, M. Rolfe, S.C. Hasmall, J.D. Tugwood, P.R. Holden, R.A. Roberts, Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis **102–103,** 91
Jeon, Y.J., see Lee, Y.W. **102–103,** 79
Jermiin, L.S., see Board, P. **102–103,** 149
Johnston, W., see Spencer, P.S. **102–103,** 515
Joos, S.K., see Spencer, P.S. **102–103,** 515
Jorkasky, D.K., What does the clinician want to know from the toxicologist? **102–103,** 539
Joshi, S., see Strauss, L. **102–103,** 349

Kadlubar, F.F., see Shirai, T. **102–103,** 441
Kaminski, N.E., Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds **102–103,** 59
Kasper, P., see Müller, L. **102–103,** 383
Keil, U., see Duhme, H. **102–103,** 307
Kerb, R., see Brockmöller, J. **102–103,** 173
Kerdine, S., see Pallardy, M. **102–103,** 257
Kersten, B., see Müller, L. **102–103,** 383
Kimber, I., Allergy, asthma and the environment: an introduction **102–103,** 301
Kintz, P., Hair testing and doping control in sport **102–103,** 109
Kirchner, S., see Gocke, E. **102–103,** 375
Kodavanti, P.R.S., see Tilson, H.A. **102–103,** 631
Koren, H., M. O'Neill, Experimental assessment of the influence of atmospheric pollutants on respiratory disease **102–103,** 317
Kortboyer, J.M., see Meulenbelt, J. **102–103,** 35
Koskinen, M., see Rajaniemi, H. **102–103,** 453
Koskinen, M., see Zhao, C. **102–103,** 591
Krämer, U., see Winneke, G. **102–103,** 423
Krammer, P.H., The CD95(APO-1/Fas)/ CD95L system **102–103,** 131
Kurt, T.L., Epidemiological association in US veterans between Gulf War illness and exposures to anticholinesterases **102–103,** 523
Kyrtopoulos, S.A., O^6-Alkylguanine-DNA alkyltransferase: influence on susceptibility to the genetic effects of alkylating agents **102–103,** 53

Lasarev, M.R., see Spencer, P.S. **102–103,** 515
Laskin, D.L., D.E. Heck, J.D. Laskin, Role of inflammatory cytokines and nitric oxide in hepatic and pulmonary toxicity **102–103,** 289
Laskin, J.D., see Laskin, D.L. **102–103,** 289
Lebrec, H., see Pallardy, M. **102–103,** 257
LeClaire, J., O. de Silva, Industry experience with alternative methods **102–103,** 575
Lee, J., see Boekelheide, K. **102–103,** 503
Lee, Y.W., S.H. Han, J.H. Suh, Y.J. Jeon, K-H. Yang, Down-regulation of protein kinase C: a potential mechanism for 2-amino-3-methylimidazo[4,5-f]quinoline-mediated immunosuppression **102–103,** 79
Leist, M., see Nicotera, P. **102–103,** 139
Lesca, P., see Pineau, T. **102–103,** 459
Li, G., see Boekelheide, K. **102–103,** 503
Livni, N., see Shapira, M. **102–103,** 205
Loikkanen, J., see Savolainen, K.M. **102–103,** 363
Luster, M.I., P.P. Simeonova, Asbestos induces inflammatory cytokines in the lung through redox sensitive transcription factors **102–103,** 271

Macdonald, N., see James, N.H. **102–103,** 91
Mäkelä, S., see Strauss, L. **102–103,** 349
Mäntylä, E., see Rajaniemi, H. **102–103,** 453
Marion, M.-J., Critical genes as early warning signs: example of vinyl chloride **102–103,** 603
Mashiba, T., see Tanizawa, T. **102–103,** 399
Matsubayashi, H., see Albuquerque, E.X. **102–103,** 211
Mazur, S., see Bohr, V. **102–103,** 47
McCauley, L.A., see Spencer, P.S. **102–103,** 515
McDougal, A., see Safe, S. **102–103,** 343
McWilliam, A.S., P.G. Holt, Immunobiology of dendritic cells in the respiratory tract: steady-state and inflammatory sentinels **102–103,** 323
Medrano, C.J., see Fox, D.A. **102–103,** 359
Ménez, A., see Servent, D. **102–103,** 199
Mensinga, T.T., see Meulenbelt, J. **102–103,** 35
Meulenbelt, J., T.T Mensinga, J.M. Kortboyer, G.J.A. Speijers, I. De Vries, Healthy volunteer studies in toxicology **102–103,** 35
Meyerson, M., Telomerase enzyme activation and human cell immortalization **102–103,** 41
Mitsumori, K., A Japanese view on a global toxicology testing program before ICH1 and after ICH4 **102–103,** 557
Miyajima, A., see Ohno, Y. **102–103,** 569
Montecucco, C., see Pellizzari, R. **102–103,** 191
Moretto, A., Experimental and clinical toxicology of anticholinesterase agents **102–103,** 509
Morton, D.M., Importance of species selection in drug toxicity testing **102–103,** 545
Mourier, G., see Servent, D. **102–103,** 199
Müller, L., P. Kasper, B. Kersten, J. Zhang, Photochemical genotoxicity and photochemical carcinogenesis — Two sides of a Coin? **102–103,** 383
Mundy, W.R., see Tilson, H.A. **102–103,** 631
Muster, W., see Gocke, E. **102–103,** 375

Naarala, J., see Savolainen, K.M. **102–103,** 363
Nakadate, M., Toxicity prediction of chemicals based on structure-activity relationships **102–103,** 627
Navarra, P., see Tringali, G. **102–103,** 295
Nicotera , P.L., see Pellizzari, R. **102–103,** 191
Nicotera, P., M. Leist, E. Ferrando-May, Intracellular ATP, a switch in the decision between apoptosis and necrosis **102–103,** 139
Nishida, S., see Tanizawa, T. **102–103,** 399
Nolan, B.M., see Carthew, P. **102–103,** 411
Nomura, T., see Yamamoto, S. **102–103,** 473
Nomura, Y., A transient brain ischemia- and bacterial endotoxin-induced glial iNOS expression and NO-induced neuronal apoptosis **102–103,** 65

O'Neill, M., see Koren, H. **102–103,** 317
O'Hare, K.B., see Williams, G.T. **102–103,** 485
Ohno, Y., A. Miyajima, M. Sunouchi, Alternative methods for mechanistic studies in toxicology. Screening of hepatotoxicity of pesticides using freshly isolated and primary cultured hepatocytes and non-liver-derived cells, SIRC cells **102–103,** 569
Olson, H., G. Betton, J. Stritar, D. Robinson, The predictivity of the toxicity of pharmaceuticals in humans from animal data — an interim assessment **102–103,** 535
Orrenius, S., see Hampton, M.B. **102–103,** 355

Pallardy, M., S. Kerdine, H. Lebrec, Testing strategies in immunotoxicology **102–103,** 257
Parkin, D.M., Epidemiology of cancer: global patterns and trends **102–103,** 227

Pellizzari, R., O. Rossetto, P. Washbourne, F. Tonello, P.L Nicotera , C. Montecucco, In vitro biological activity and toxicity of tetanus and botulinum neurotoxins **102–103,** 191
Pereira, E.F.R., see Albuquerque, E.X. **102–103,** 211
Pfeifer, G.P., M.F. Dennissenko, M-S. Tang, PCR-based approaches to adduct analysis **102–103,** 447
Pfohl-Leszkowicz, A., see Pineau, T. **102–103,** 459
Pineau, T., P. Costet, O. Puel, A. Pfohl-Leszkowicz P. Lesca, M. Alvinerie, P. Galtier, Knockout animals in toxicology: assessment of toxin bioactivation pathways using mice deficient in xenobiotic metabolizing enzymes **102–103,** 459
Poblenz, A.T., see Fox, D.A. **102–103,** 359
Porter, W., see Safe, S. **102–103,** 343
Portier, C.J., D.A. Bell, Genetic susceptibility: significance in risk assessment **102–103,** 185
Potten, C.S., see Pritchard, D.M. **102–103,** 19
Preziosi, P., see Tringali, G. **102–103,** 295
Priestly, B.G., see Di Marco, P.N. **102–103,** 241
Pritchard, D.M., A. Jackman, C.S. Potten, J.A. Hickman, Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity **102–103,** 19
Puel, O., see Pineau, T. **102–103,** 459

Rajaniemi, H., M. Koskinen, E. Mäntylä, K. Hemminki, DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver **102–103,** 453
Ray, D.E., Chronic effects of low level exposure to anticholinesterases — a mechanistic review **102–103,** 527
Reisdorf, P., see Choisy-Rossi, C. **102–103,** 491
Remandet, B., see Dean, J.H. **102–103,** 247
Rice, J.M., see Chomarat, P. **102–103,** 595
Richard, A.M., Commercial toxicology prediction systems: a regulatory perspective **102–103,** 609
Richburg, J.H., see Boekelheide, K. **102–103,** 503
Roberts, R.A., see James, N.H. **102–103,** 91
Robinson, D., see Olson, H. **102–103,** 535
Rolfe, M., see James, N.H. **102–103,** 91
Roots, I., see Brockmöller, J. **102–103,** 173
Rossetto, O., see Pellizzari, R. **102–103,** 191
Russo, C.D., see Tringali, G. **102–103,** 295

Saarinen, N., see Strauss, L. **102–103,** 349
Sachse, C., see Brockmöller, J. **102–103,** 173
Safe, S., F. Wang, W. Porter, R. Duan, A. McDougal, Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms **102–103,** 343
Safe, S., K. Connor, K. Gaido, Methods for xenoestrogen testing **102–103,** 665
Santti, R., see Strauss, L. **102–103,** 349
Savolainen, K.M., J. Loikkanen, S. Eerikäinen, J. Naarala, Interactions of excitatory neurotransmitters and xenobiotics in excitotoxicity and oxidative stress: glutamate and lead **102–103,** 363
Scallet, A.C., see Slikker Jr, W. **102–103,** 429
Schmidt, E., see Winneke, G. **102–103,** 423
Schuell, T., see Spencer, P.S. **102–103,** 517
Seidman, S., see Shapira, M. **102–103,** 205
Servent, D., G. Mourier, S. Antil, A. Ménez, How do snake curaremimetic toxins discriminate between nicotinic acetylcholine receptor subtypes **102–103,** 199
Shapira, M., S. Seidman, N.Livni, H. Soreq, In vivo and in vitro resistance to multiple anticholinesterases in *Xenopus laevis* tadpoles **102–103,** 205
Shimoda, K., Mechanisms of quinolone phototoxicity **102–103,** 369
Shipp, E.B., see Boekelheide, K. **102–103,** 503
Shirai, T., S. Takahashi, L. Cui, Y. Yamada, M. Tada, F.F. Kadlubar, N. Ito, Use of polyclonal antibodies against carcinogen-DNA adducts in analysis of carcinogenesis **102–103,** 441
Simeonova, P.P., see Luster, M.I. **102–103,** 271
Slagle, B.L., see Chomarat, P. **102–103,** 595
Slikker Jr, W., A.C. Scallet, D.W. Gaylor, Biologically-based dose–response model for neurotoxicity risk assessment **102–103,** 429
Smart, J., see Daly, A.K. **102–103,** 143
Soreq, H., see Shapira, M. **102–103,** 205
Spalding, J.W., see Tennant, R.W. **102–103,** 465
Speijers, G.J.A., see Meulenbelt, J. **102–103,** 35
Spencer, P.S., L.A. McCauley, S.K. Joos, M.R. Lasarev, T. Schuell, D. Bourdette, A. Barkhuizen, W. Johnston, D. Storzbach, M. Wynn, R. Grewenow, U.S. Gulf War Veterans: Service periods in theater, differential exposures, and persistent unexplained illness **102–103,** 515
Srivastava, D., see Fox, D.A. **102–103,** 359
Steingrüber, H-J., see Winneke, G. **102–103,** 423
Stern, R.S., Photocarcinogenicity of drugs **102–103,** 389
Storzbach, D., see Spencer, P.S. **102–103,** 515
Stott, W.T., see Gollapudi, B.B. **102–103,** 479
Strauss, L., R. Santti, N. Saarinen, T. Streng, S. Joshi, S. Mäkelä, Dietary phytoestrogens and their role in hormonally dependent disease **102–103,** 349
Streng, T., see Strauss, L. **102–103,** 349
Stritar, J., see Olson, H. **102–103,** 535
Suh, J.H. see Lee, Y.W. **102–103,** 79
Sumpter, J.P., Xenoendocrine disrupters — environmental impacts **102–103,** 337
Sunouchi, M., see Ohno, Y. **102–103,** 569

Tada, M., see Shirai, T. **102–103,** 441
Takahashi, H.E., see Tanizawa, T. **102–103,** 399
Takahashi, S., see Shirai, T. **102–103,** 441
Takano, Y., see Tanizawa, T. **102–103,** 399
Tang, M-S., see Pfeifer, G.P. **102–103,** 447
Tanizawa, T., N. Yamamoto, Y. Takano, T. Mashiba, L. Zhang, S. Nishida, N. Endo, H.E. Takahashi, R. Fujimoto, M. Hori, Effects of human PTH(1-34) and bisphosphonate on the osteopenic rat model **102–103,** 399
Tenenbein, M., Toxicokinetics and toxicodynamics of iron poisoning **102–103,** 653
Tennant, R.W., R.R. Tice, J.W. Spalding, The transgenic Tg.AC mouse model for identification of chemical carcinogens **102–103,** 465
Tice, R.R., see Tennant, R.W. **102–103,** 465
Tilly, J.L., Molecular and genetic basis of normal and toxicant-induced apoptosis in female germ cells **102–103,** 497
Tilson, H.A., P.R.S. Kodavanti, W.R. Mundy, P.J. Bushnell,

Neurotoxicity of environmental chemicals and their mechanism of action **102–103,** 631
Tonello, F., see Pellizzari, R. **102–103,** 191
Tringali, G., C.D. Russo, P. Preziosi, P. Navarra, Hypothalamic interleukin-1 in physiology and pathology **102–103,** 295
Trosko, J.E., C-C. Chang, B. Upham, M. Wilson, Epigenetic toxicology as toxicant-induced changes in intracellular signalling leading to altered gap junctional intercellular communication **102–103,** 71
Tugwood, J.D., see James, N.H. **102–103,** 91
Turteltaub, K.W., K.H. Dingley, Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification **102–103,** 435

Upham, B., see Trosko, J.E. **102–103,** 71
Urano, K., see Yamamoto, S. **102–103,** 473

Vainio, H., Use of biomarkers — new frontiers in occupational toxicology and epidemiology **102–103,** 581
Vale, J.A., Toxicokinetic and toxicodynamic aspects of organophosphorus (OP) insecticide poisoning **102–103,** 649
Van Loveren, H., W.H. De Jong, R.J. Vandebriel, J.G. Vos, J. Garssen, Risk assessment and immunotoxicology **102–103,** 261
van der Laan, J.W., New perspectives for alternative approaches to carcinogenicity testing: a regulator viewpoint **102–103,** 561
Vandebriel, R.J., see Van Loveren, H. **102–103,** 261
Vos, J.G., see Van Loveren, H. **102–103,** 261

Walkowiak, J., see Winneke, G. **102–103,** 423
Wang, F., see Safe, S. **102–103,** 343
Washbourne, P., see Pellizzari, R. **102–103,** 191
Watanabe, M., Polymorphic CYP genes and disease predisposition — what have the studies shown so far? **102–103,** 167
Weiland, S.K., see Duhme, H. **102–103,** 307
Weissenbach, J., Human genome mapping and sequencing: perspectives for toxicology **102–103,** 1
Wiener, J-A., see Winneke, G. **102–103,** 423
Wild, C.P., see Chomarat, P. **102–103,** 595
Williams, G.T., M.R. Critchlow, V.L. Hedge, K.B. O'Hare, Molecular failure of apoptosis: inappropriate cell survival and mutagenesis? **102–103,** 485
Wilson, M., see Trosko, J.E., **102–103,** 71
Winneke, G., A. Bucholski, B. Heinzow, U. Krämer, E. Schmidt, J. Walkowiak, J-A. Wiener, H-J. Steingrüber, Developmental neurotoxicity of polychlorinated biphenyls (PCBS): cognitive and psychomotor functions in 7-month old children **102–103,** 423
Woodyatt, N.J., see James, N.H. **102–103,** 91
Wynn, M., see Spencer, P.S. **102–103,** 515

Yamada, Y., see Shirai, T. **102–103,** 441
Yamamoto, N., see Tanizawa, T. **102–103,** 399
Yamamoto, S., K. Urano, T. Nomura, Validation of transgenic mice harboring the human prototype c-Ha-*ras* gene as a bioassay model for rapid carcinogenicity testing **102–103,** 473
Yang, K-H., see Lee, Y.W. **102–103,** 79
Yano, B.L., see Gollapudi, B.B. **102–103,** 479
Yonish-Rouach, E., see Choisy-Rossi, C. **102–103,** 491

Zhang, J., see Müller, L. **102–103,** 383
Zhang, L., see Tanizawa, T. **102–103,** 399
Zhao, C., M. Koskinen, K. Hemminki, ^{32}P-postlabelling of N^6-adenine adducts of epoxybutanediol in vivo after 1,3-butadiene exposure **102–103,** 591
Zhuang, J., G.M. Cohen, Release of mitochondrial cytochrome *c* is upstream of caspase activation in chemical-induced apoptosis in human monocytic tumour cells **102–103,** 121

ELSEVIER

Toxicology Letters 102–103 (1998) 687–690

Toxicology Letters

Subject index

Volumes 102–103 (1998)

N-Nitroso compounds **102–103**, 53
O^6-Methylguanine **102–103**, 53
^{32}P-postlabelling **102–103**, 453, 591
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin **102–103**, 343
2-Amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline **102–103**, 435
2-Amino-3-methylimidazo[4,5-*f*]quinoline **102–103**, 79
5-Fluorouracil **102–103**, 19

ATP **102–103**, 139
Accelerator mass spectrometry **102–103**, 435
Acetaminophen **102–103**, 161
Acetyl carnitine **102–103**, 5
Acetylcholinesterase inhibitors **102–103**, 527
Acetylcholinesterase **102–103**, 205, 509, 523
Adverse effects **102–103**, 155
Aging **102–103**, 47
Ah receptor **102–103**, 143, 343
Air pollution **102–103**, 317
Alternative methods **102–103**, 569, 575
Amantadine **102–103**, 211
Analytical toxicology **102–103**, 103
Angiosarcoma **102–103**, 603
Antiandrogens **102–103**, 331, 677
Antidote **102–103**, 643
Antiestrogens **102–103**, 343
Antitumor agents **102–103**, 343
Apoptosis **102–103**, 19, 65, 91, 115, 121, 131, 139, 355, 359, 363, 485, 491, 497, 503
Arylamine **102–103**, 173
Asbestos **102–103**, 271
Asthma **102–103**, 301, 307, 317
Astrocytes **102–103**, 283
Autoimmunity **102–103**, 257, 267
Avian test system **102–103**, 671
Azathioprine **102–103**, 247

Base excision repair **102–103**, 235
bcl-2 **102–103**, 485
Benzo[*a*]pyrene **102–103**, 447
Bioassays **102–103**, 465
Biodynamic models **102–103**, 35
Bioinformatics **102–103**, 149
Biokinetic models **102–103**, 35
Biological variability **102–103**, 617
Biologically-based dose–response model **102–103**, 429
Biomarker **102–103**, 417
Bird egg **102–103**, 671
Bisphenol A **102–103**, 665
Bisphosphonate **102–103**, 399
Botulism **102–103**, 191
Breast cancer **102–103**, 453

c-Ha-*ras* human **102–103**, 473
cAMP **102–103**, 59
cGMP PDE **102–103**, 359
CASE **102–103**, 611
CD95(APO-1/Fas) **102–103**, 131
CYP1A1 **102–103**, 143
CYP2E1 **102–103**, 143
Caffeine **102–103**, 161
Calcium **102–103**, 359, 631
Cancer epidemiology **102–103**, 219, 227
Cancer susceptibility **102–103**, 167
Cancer **102–103**, 41, 173
Cannabinoids **102–103**, 59
Cannabinol **102–103**, 59
Carbamates **102–103**, 205
Carcinogen-DNA adduct antibody **102–103**, 441
Carcinogen **102–103**, 241
Carcinogenesis **102–103**, 479
Carcinogenic potential **102–103**, 565
Carcinogenicity testing **102–103**, 473
Carcinogenicity **102–103**, 235, 561
Case-control study **102–103**, 515
Caspases **102–103**, 121, 355, 485
Cell cycle **102–103**, 115
Cell immortalization **102–103**, 41
Cell proliferation **102–103**, 19
Cephaloridine **102–103**, 29
Cerebral ischemia **102–103**, 65
Chemical carcinogenesis **102–103**, 465, 473
Chemical product development **102–103**, 623
Chemotherapy **102–103**, 497
Children **102–103**, 423
Clostridia **102–103**, 191

Cocaine **102–103**, 97
Cognitive function **102–103**, 527
Colon **102–103**, 115
Commercial prediction systems **102–103**, 611
Compound A of sevoflurane **102–103**, 29
Computational toxicology **102–103**, 623
Confounding **102–103**, 423
Congener-specific effects **102–103**, 631
Cosmetics **102–103**, 575
Curaremimetic toxins **102–103**, 199
Cyclic GMP **102–103**, 295
Cyclophosphamide **102–103**, 247
Cyclosporin A **102–103**, 247
Cytochrome *c* **102–103**, 121
Cytochrome P450 **102–103**, 143, 161, 173, 459, 595
Cytokines **102–103**, 271, 277, 283
Cytostatic drugs **102–103**, 53

DDE **102–103**, 331
DEREK **102–103**, 611
DMAB **102–103**, 441
DNA adducts **102–103**, 435, 447, 453, 591
DNA damage **102–103**, 5
DNA synthesis **102–103**, 91
Deferoxamine **102–103**, 653
Dendritic cells **102–103**, 323
Deployment period **102–103**, 515
Developmental neurotoxicology **102–103**, 631
Dexamethasone **102–103**, 247
Diagnosis **102–103**, 643
Differential display **102–103**, 491
Dioxins **102–103**, 331
Disease susceptibility **102–103**, 173
Disinfection byproducts **102–103**, 611
Domoic acid **102–103**, 429
Doping control **102–103**, 109
Dose–response **102–103**, 185
Drug abuse testing **102–103**, 103
Drug development **102–103**, 623, 657
Drug disposition **102–103**, 545
Drug metabolism **102–103**, 479
Drug metabolizing enzymes **102–103**, 167

Endocrine disruption **102–103**, 337, 343, 349, 671, 677
Endocrine system **102–103**, 665
Endotoxin **102–103**, 65
Environmental pollution **102–103**, 301
Epidemiology **102–103**, 307, 523
Epigenetic toxicology **102–103**, 71
Epoxybutanediol **102–103**, 591
Estrogen receptor **102–103**, 665
Estrogens **102–103**, 331, 337, 677
Excitotoxic amino acids **102–103**, 429
Excitotoxicity **102–103**, 363
Experimental assessment **102–103**, 317
Exposure chambers **102–103**, 317
Extrapolation **102–103**, 261

Fas system **102–103**, 485, 503
Fatigue **102–103**, 515
Fatty acids **102–103**, 85
Fluoroquinolones **102–103**, 383
Folic acid **102–103**, 5
Future aims of ICH **102–103**, 551

GST **102–103**, 595
Gap junctions **102–103**, 71
Gastrointestinal toxicity **102–103**, 19
Gene knockout **102–103**, 161
Genetic polymorphism **102–103**, 143, 149, 155, 161, 167, 173
Genotoxicant **102–103**, 235, 241, 497
Germ cell **102–103**, 497, 503
Global trends **102–103**, 227
Glutamate **102–103**, 363
Glutathione *S*-transferase **102–103**, 173
Growth arrest **102–103**, 491
Gulf War **102–103**, 515, 523

HPLC **102–103**, 591
Hair **102–103**, 109
Harmonisation **102–103**, 241, 551
Hepatocarcinogenesis **102–103**, 85
Hepatotoxicity **102–103**, 569, 653
Heroin **102–103**, 97
Hippocampal slices **102–103**, 211
Histomorphometry **102–103**, 399
Homeostasis **102–103**, 631
Human PTH **102–103**, 399
Human cancer **102–103**, 219
Human genome project **102–103**, 1
Human toxicity **102–103**, 539
Human volunteer studies **102–103**, 35
Hyperplasia **102–103**, 411
Hypersensitivity **102–103**, 257, 267
Hypertrophy **102–103**, 411
Hypolipidemic drugs **102–103**, 85
Hypothalamus **102–103**, 295

iNOS expression **102–103**, 65
ICH guideline **102–103**, 551, 557, 657
Identification **102–103**, 103
Immune response **102–103**, 283, 355
Immunosuppression **102–103**, 59, 79, 267
Immunotoxicity evaluation **102–103**, 247
Immunotoxicology **102–103**, 257, 261, 267
In vitro testing **102–103**, 417
Individual susceptibility **102–103**, 581
Infection **102–103**, 301, 323
Infertility **102–103**, 497
Inflammation **102–103**, 271, 323
Interleukin-1 **102–103**, 295
Intermediate syndrome **102–103**, 509
International Olympic Committee **102–103**, 109
Internet **102–103**, 623

Intersex fish **102–103**, 337
Iron **102–103**, 653

Japanese regulation **102–103**, 557

Keratinocytes **102–103**, 277
Knockout animals **102–103**, 459

Lead **102–103**, 359, 363
Lipoic acid **102–103**, 5
Lithium **102–103**, 637
Liver cancer **102–103**, 595
Liver **102–103**, 115, 411
Local effects **102–103**, 575
Low level dosimetry **102–103**, 435
Lung cancer **102–103**, 167
Lung **102–103**, 271
Lymphoma **102–103**, 115

Macrophages **102–103**, 289
Marijuana **102–103**, 97
Mathematical modeling **102–103**, 185
Melanoma **102–103**, 389
Mental development **102–103**, 423
Metabolic polymorphisms **102–103**, 581
Metabolic profile **102–103**, 545
Metabolism **102–103**, 459
Metals **102–103**, 235
Methylating agents **102–103**, 53
Mitochondria **102–103**, 359
Mitochondrial membrane potential **102–103**, 121
Molecular epidemiology **102–103**, 219, 581
Morphometry **102–103**, 393, 411
MultiCASE **102–103**, 611
Musculoskeletal and cognitive symptoms **102–103**, 515
Mutagenesis **102–103**, 447, 479, 485, 627

NO **102–103**, 65
Nandrolone **102–103**, 109
Necrotic cell death **102–103**, 363
Nephrotoxicity **102–103**, 29
Neuronal apoptosis **102–103**, 65
Neuropathology **102–103**, 393
Neurotoxicity risk assessment **102–103**, 429
Neurotoxicity **102–103**, 417
Neurotoxins **102–103**, 191
New molecular entities **102–103**, 247
Nicotinic receptors **102–103**, 199, 211
Nitric oxide **102–103**, 289
Non-genotoxic carcinogenesis **102–103**, 91, 241
Nonylphenol **102–103**, 665
Nucleotide excision repair **102–103**, 235

Occupational exposure **102–103**, 603
Ochratoxin A **102–103**, 29
Oocyte **102–103**, 497
Optical dissector **102–103**, 411
Organic anion transporter **102–103**, 29
Organic cation transporter **102–103**, 29
Organophosphates **102–103**, 205, 417, 509
Organophosphorus pesticides **102–103**, 527, 649
Osteoporosis **102–103**, 399
Ovariectomy **102–103**, 399
Ovary **102–103**, 497
Oxidative damage **102–103**, 47
Oxidative stress **102–103**, 363
Ozone **102–103**, 289

$p21^{waf\text{-}1/cip1}$ **102–103**, 19
$p21^{ras}$ **102–103**, 603
p53 antibodies **102–103**, 603
p53 **102–103**, 19, 115, 447, 491, 603
P450 **102–103**, 479
PCB **102–103**, 423
PKC translocation **102–103**, 631
Parallellogram approach **102–103**, 261
Parathyroid toxicity **102–103**, 405
Patch-clamp **102–103**, 211
Peripheral neuropathy **102–103**, 509
Peroxisome proliferator activated receptor α (PPARα) **102–103**, 91
Peroxisome proliferators **102–103**, 85, 91
Pesticides **102–103**, 569
PhIP **102–103**, 441
Pharmaceutical development **102–103**, 623
Pharmaceutical industry **102–103**, 247
Pharmaceutical toxicity **102–103**, 535
Pharmaceuticals **102–103**, 557, 565
Pharmacodynamic **102–103**, 643
Pharmacokinetics **102–103**, 97, 643
Phase I testing **102–103**, 539
Phase II enzymes **102–103**, 149
Phenobarbital **102–103**, 411
Photochemical carcinogenesis **102–103**, 383
Photochemical genotoxicity **102–103**, 383
Photodynamic action **102–103**, 375
Photosensitizer **102–103**, 389
Phototoxicity **102–103**, 369, 383
Phthalates **102–103**, 331
Phytoestrogen **102–103**, 349
Pollution **102–103**, 307
Polychlorinated biphenyls **102–103**, 631
Polymorphism **102–103**, 185
Posttranslational modification **102–103**, 71
Primary cultured rat hepatocytes **102–103**, 569
Procymidone **102–103**, 331
Prognosis **102–103**, 643
Promotion **102–103**, 509
Proteases **102–103**, 139, 355
Protein kinase C **102–103**, 79
Psoralen **102–103**, 389
Psychomotor functions **102–103**, 423

Quantitative histological techniques **102–103**, 429

Quantitative structure activity relationships **102–103**, 617
Quinolone **102–103**, 369

rasH2 mouse **102–103**, 473
Rabbit eye cell line **102–103**, 569
Radical formation **102–103**, 653
Reactive oxygen species **102–103**, 369, 375
Redox **102–103**, 355
Regulatory guidance **102–103**, 267
Regulatory acceptance **102–103**, 561
Reproduction **102–103**, 331
Respiratory allergy **102–103**, 301
Respiratory tract **102–103**, 323
Retina **102–103**, 359
Risk assessment **102–103**, 35, 185, 241, 261, 417, 423, 453, 539

SAR **102–103**, 609, 611, 627
SNARE **102–103**, 191
Safety pharmacology **102–103**, 539
Screening **102–103**, 103, 569
Sequence-specific transcriptional activation **102–103**, 491
Sertoli cell **102–103**, 503
Sex differentiation **102–103**, 671
Shock **102–103**, 653
Signal transduction **102–103**, 71
Signaling in apoptosis **102–103**, 131
Singlet oxygen **102–103**, 375
Skin cancer **102–103**, 375
Skin irritation **102–103**, 277
Skin sensitization **102–103**, 261
Skin tolerance **102–103**, 575
Skin **102–103**, 369, 389
Snake toxins **102–103**, 199
Species selection **102–103**, 545
Species specificity **102–103**, 535
Squamous cell cancer **102–103**, 389
Stereology **102–103**, 393
Structure-activity relationship **102–103**, 617, 627
Strychnine **102–103**, 211
Sulfamethazine **102–103**, 405

TOPKAT **102–103**, 611
Tamoxifen **102–103**, 453
Target organ toxicity **102–103**, 535
Telomerase **102–103**, 41
Test guideline **102–103**, 557
Testis **102–103**, 503
Tetanus **102–103**, 191
Tetrahydrocannabinol **102–103**, 59, 97
Tg.AC mice **102–103**, 465
Threshold **102–103**, 241
Thyroid toxicity **102–103**, 405
Time trends **102–103**, 227
Toxicity evaluation **102–103**, 623, 657
Toxicity prediction **102–103**, 609, 611, 627
Toxicodynamics **102–103**, 637, 649, 657
Toxicogenetics **102–103**, 1
Toxicopathology **102–103**, 393
Transcriptional activation **102–103**, 71
Transgenic animals **102–103**, 161, 465, 473, 475, 479, 561
Transgenic expression **102–103**, 205
Transgenic models **102–103**, 465
Transmitter release **102–103**, 211
Tumorigenesis **102–103**, 115
Tumour necrosis factor α (TNFα) **102–103**, 91

Ultrarapid metabolisers **102–103**, 155
Ultraviolet light **102–103**, 389, 447
Urinary bladder cancer **102–103**, 167

Vinclozolin **102–103**, 331
Vinyl chloride **102–103**, 603
Vitamins **102–103**, 5

Wine extract **102–103**, 665

X protein **102–103**, 595
Xenobiotic **102–103**, 459
Xenoestrogen testing **102–103**, 665
Xenoestrogens **102–103**, 337
Xenopus laevis **102–103**, 205

Zinc-endopeptidases **102–103**, 191